p-medicine - From Data Sharing and Integration via VPH Models to Personalized Medicine

p-medicine is a 4-year Integrated Project co-funded under the European Community's 7th Framework Programme aiming at developing new tools, IT infrastructure and VPH models to accelerate personalized medicine for the benefit of the patient.

19 project partners from 9 European countries and Japan have dedicated themselves to create support and sustain new knowledge and innovative technologies to overcome current problems in clinical research and pave the way for a more individualized therapy.

Medicine is undergoing a revolution transforming the nature of healthcare from reactive to preventive. This change is catalyzed by a new systems approach which focuses on integrated diagnosis, treatment and prevention of disease in individuals eventually leading to a personalized predictive treatment. p-medicine brings together international leaders in their fields to create an infrastructure that will facilitate this translation from current practice to personalized medicine.

p-medicine project has formulated a coherent, integrated workplan for the design, development, integration of an open, modular framework of tools and services so that p-medicine can be adopted gradually, including efficient secure sharing and handling of large personalized data sets, enabling demanding Virtual Physiological Human (VPH) multiscale simulations (in silico oncology), building standards-compliant tools and models for VPH research, drawing on the VPH Toolkit and providing tools for large-scale, privacy-preserving data and literature mining, a key component of VPH research.

It is understood that privacy, non-discrimination, and access policies are aligned to maximize protection of and benefit to patients. The p-medicine tools and technologies will be validated within the concrete setting of advanced clinical research. Pilot cancer trials have been selected based on clear research objectives, emphasising the need to integrate multilevel datasets, in the domains of Wilms tumour, breast cancer and leukaemia. To sustain a self-supporting infrastructure realistic use cases will be built demonstrating tangible results for clinicians.

For further information, please visit:
http://www.p-medicine.eu

Related article:

About p-medicine project
The European Integrated Project p-medicine is supported by the European Commission under the 7th Framework Programme, Grant agreement number 270089.

Most Popular Now

Elsevier Adds to its Extensive Free Reso…

Elsevier, a global leader in information analytics specializing in science and health, is offering free access to a unique set of biomedical research tools and content to help researchers and...

Cancer Care Model could Help Us Cope wit…

As the UK government looks for an exit strategy to Britain's COVID-19 lockdown a nanomedicine expert from The University of Manchester believes a care model usually applied to cancer patients...

An EU Approach for Efficient Contact Tra…

EU Members States, supported by the Commission, have developed an EU toolbox for the use of mobile applications for contact tracing and warning in response to the coronavirus pandemic. This...

COVID-19 and Health Tech: Building on th…

Highland Marketing's advisory board met to discuss the health tech response to the coronavirus outbreak. In many areas, this has been hugely impressive: but there are gaps, and there will...

New AI Diagnostic can Predict COVID-19 w…

Researchers at King's College London, Massachusetts General Hospital and health science company ZOE have developed an artificial intelligence diagnostic that can predict whether someone is likely to have COVID-19 based...

Biomax Provides AI-Based Semantic Search…

The bioinformatics company Biomax, headquartered in Planegg, Germany, makesitssemantic search platform AILANI available free of charge to research institutes around the world in order to support the rapid and successful...

InsurTech Hub Munich and dmac/Digital He…

InsurTech Hub Munich (ITHM) and dmac - Medical Valley Digital Health Application Center part of the Digital Health Hub Nuremberg/Erlangen announce a new cross-industry accelerator for the second half of...

Telemedicine Transforms Response to COVI…

A rapid increase in "virtual" visits during the COVID-19 pandemic could transform the way physicians provide care in the United States going forward, according to a new study led by...

Supercomputer Simulations Present Potent…

Several drugs approved for treating hepatitis C viral infection were identified as potential candidates against COVID-19, a new disease caused by the SARS-CoV-2 coronavirus. This is the result of research...

Viveo Health Offers Free Telemedicine So…

Viveo Health, a global e-Health innovator, is making its 'Virtual Office for Doctors' platform free of charge to doctors and other medical professionals worldwide in light of the surge in...

The Dedalus Group, Participated by Ardia…

The Dedalus Group, a leading European company, and one of the worldwide main ones, active in clinical healthcare information systems to support clinical professionals and organizations in order to improve...

The COVID-19 pandemic reveals the potent…

Two new articles provide insights on the use of telehealth or virtual care in the age of COVID-19 and beyond, pointing to its value to not only prevent contagious diseases...